Dolutegravir & Abacavir & Lamivudine
Treats HIV infection. Don't stop taking your medication unless your doctor tells you otherwise. Don't miss any doses. Stopping this medication or missing doses can make it more difficult to treat HIV.
Dolutegravir & Abacavir & Lamivudine Overview
Dolutegravir is an integrase strand transfer inhibitor (INSTI). These help to increase the number of immune cells that help fight infections in your body.
Abacavir and lamivudine belong to a group of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). Together these medications help to increase the number of immune cells that help fight infections in your body and decrease the amount of HIV in the blood.
This medication comes in tablet form and is taken typically once a day.
Common side effects of dolutegravir/abacavir/lamivudine include insomnia (trouble sleeping), headache, and fatigue (tiredness).
Dolutegravir/abacavir/lamivudine can cause fatigue (tiredness). Do not drive or operate heavy machinery until you know how dolutegravir/abacavir/lamivudine affects you.
How was your experience with ?
Uses of Dolutegravir & Abacavir & Lamivudine
Dolutegravir/abacavir/lamivudine is a prescription medication used to treat HIV infection.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Dolutegravir & Abacavir & Lamivudine Brand Names
Dolutegravir & Abacavir & Lamivudine may be found in some form under the following brand names:
Dolutegravir & Abacavir & Lamivudine Drug Class
Dolutegravir & Abacavir & Lamivudine is part of the drug class:
Side Effects of Dolutegravir & Abacavir & Lamivudine
Serious side effects have been reported with dolutegravir/abacavir/lamivudine. See the “Dolutegravir/abacavir/lamivudine Precautions” section.
Common side effects of dolutegravir/abacavir/lamivudine include the following:
- insomnia (trouble sleeping)
- fatigue (tiredness)
This is not a complete list of dolutegravir/abacavir/lamivudine side effects. Ask your doctor or pharmacist for more information.
Tell your doctor if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Dolutegravir & Abacavir & Lamivudine Interactions
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take:
- antacids, laxatives, or other medicines that contain aluminum, magnesium, sucralfate (Carafate), or buffered medicines. Dolutegravir/abacavir/lamivudine should be taken at least 2 hours before or 6 hours after you take these medicines.
- anti-seizure medicines: oxcarbazepine (Trileptal), phenytoin (Dilantin, Dilantin-125, Phenytek), phenobarbital, carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR, Teril, Epitol)
- any other HIV medication
- iron or calcium supplements taken by mouth. Supplements containing calcium or iron may be taken at the same time with dolutegravir/abacavir/lamivudine if taken with food. Otherwise, dolutegravir/abacavir/lamivudine should be taken at least 2 hours before or 6 hours after you take these medicines.
- medicines used to treat hepatitis virus infections, such as interferon or ribavirin
- medicines containing metformin
- rifampin (Rifater, Rifamate, Rimactane, Rifadin
- St. John's wort (Hypericum perforatum)
This is not a complete list of dolutegravir/abacavir/lamivudine drug interactions. Ask your doctor or pharmacist for more information.
Dolutegravir & Abacavir & Lamivudine Precautions
Serious side effects have been reported with dolutegravir/abacavir/lamivudine including the following:
- serious allergic reactions. Serious allergic reactions have occurred with dolutegravir/abacavir/lamivudine and other abacavir-containing products. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701, which can be determined by a blood test from your doctor. If you experience symptoms from 2 or more of the following groups while taking dolutegravir/abacavir/lamivudine, then call your healthcare provider immediately: Group 1 fever; Group 2 rash; Group 3 nausea, vomiting, diarrhea, stomach pain; Group 4 feeling ill, extreme tiredness, achiness; Group 5 shortness of breath, cough, sore throat. Always carry the Warning Card with you listing these symptoms that is provided by your pharmacist.
- lactic acidosis (build-up of acid in your blood). Lactic acidosis is a serious medical emergency that can cause death. Call your healthcare provider right away if you experience any of the following symptoms: feeling very weak or tired, unusual muscle pain, trouble breathing, stomach pain with nausea and vomiting, feeling cold (especially in arms and legs), feeling dizzy or lightheaded, fast or irregular heartbeat.
- serious liver problems. Serious liver problems can sometimes cause death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis). Call your healthcare provider immediately if you experience any of the following symptoms: skin or white part of eyes turns yellow, dark or "tea-colored" urine, light colored stools, loss of appetite for several days or longer, nausea, and pain, aching, or tenderness on the right side of your stomach area.
- worsening of hepatitis B virus (HBV) in people who have HIV-1 infection. If you have HIV-1 and HBV infection, your HBV may get worse if you stop taking dolutegravir/abacavir/lamivudine. Do not run out of dolutegravir/abacavir/lamivudine. Refill your prescription or talk to your healthcare provider before your dolutegravir/abacavir/lamivudine is all gone. Do not stop taking dolutegravir/abacavir/lamivudine without talking to your healthcare provider. If you stop taking dolutegravir/abacavir/lamivudine, then your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver.
- resistant HBV. If you have HIV-1 and HBV, the HBV can change (mutate) during your treatment with dolutegravir/abacavir/lamivudine and become harder to treat.
- worsening liver disease in people infected with both HIV-1 and hepatitis C. Worsening of liver disease that has caused death has occurred in people taking antiretroviral medicines and also being treated for hepatitis C with interferon with or without ribavirin. If you are taking dolutegravir/abacavir/lamivudine and interferon with or without ribavirin, tell your healthcare provider if you have any new symptoms.
- drug interactions may cause more dolutegravir/abacavir/lamivudine side effects or make your HIV harder to treat. Dolutegravir/abacavir/lamivudine may interact with other medications causing dolutegravir/abacavir/lamivudine to not work as well and possible development of resistance. In addition, medications may interact with dolutegravir/abacavir/lamivudine causing more side effects. Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Do not start new medications without first talking to your doctor or pharmacist.
Do not take dolutegravir/abacavir/lamivudine if you:
- are allergic to dolutegravir/abacavir/lamivudine or to any of its ingredients
- have a certain type of gene variation called the HLA-B*5701 allele
- take dofetilide (Tikosyn). Taking dolutegravir/abacavir/lamivudine and Tikosyn can cause life-threatening side effects.
- have liver problems
Dolutegravir & Abacavir & Lamivudine Food Interactions
Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of dolutegravir/abacavir/lamivudine, there are no specific foods that you must exclude from your diet when receiving this medication.
Before taking dolutegravir/abacavir/lamivudine, tell your doctor about all of your medical conditions. Especially tell your doctor if you:
- are allergic to dolutegravir/abacavir/lamivudine or to any of its ingredients
- have been tested and know whether or not you have a gene variation called HLA-B*5701
- have or have had liver problems, including hepatitis B or C virus infection
- have kidney problems
- have heart problems, smoke, or have diseases that increase your risk of heart disease such as high blood pressure, high cholesterol, or diabetes
- drink alcohol or take medicines that contain alcohol
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed. Do not breastfeed if you take dolutegravir/abacavir/lamivudine.
Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.
Dolutegravir & Abacavir & Lamivudine and Pregnancy
Tell your doctor if you are pregnant or plan to become pregnant.
The FDA categorizes medications based on safety for use during pregnancy. Five categories-A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.
Dolutegravir/abacavir/lamivudine falls into category C. There are no well-controlled studies that have been done in pregnant women. Dolutegravir/abacavir/lamivudine should be used during pregnancy only if the possible benefit outweighs the possible risk to the unborn baby.
There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. Talk to your healthcare provider about how you can take part in this registry.
Dolutegravir & Abacavir & Lamivudine and Lactation
Do not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.
Dolutegravir & Abacavir & Lamivudine Usage
Take dolutegravir/abacavir/lamivudine exactly as prescribed.
Dolutegravir/abacavir/lamivudine comes in tablet form and is taken once a day by mouth with or without food.
If you miss a dose, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of dolutegravir/abacavir/lamivudine at the same time.
Dolutegravir & Abacavir & Lamivudine Dosage
Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.
The dose your doctor recommends may be based on the following:
- the condition being treated
- other medical conditions you have
- other medications you are taking
- how you respond to this medication
- your weight
- your height
- your age
- your gender
The recommended dose of dolutegravir/abacavir/lamivudine in adults and children weighing at least 88 lbs (40 kg) is one tablet by mouth once a day with or without food.
Dolutegravir & Abacavir & Lamivudine Overdose
If you take too much dolutegravir/abacavir/lamivudine, call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.
- Store dolutegravir/abacavir/lamivudine in the original bottle at room temperature.
- Keep the desiccant packet that protects dolutegravir/abacavir/lamivudine from moisture in the bottle.
- Keep this and all medicines out of reach of children.
- Talk to your healthcare provider about how to prevent passing HIV to other people.
- Keep all appointments with your doctor and the laboratory.
Dolutegravir & Abacavir & Lamivudine FDA Warning
BOXED WARNING: RISK OF HYPERSENSITIVITY REACTIONS, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY, AND EXACERBATIONS OF HEPATITIS B
Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir-containing products.
- Hypersensitivity to abacavir is a multi-organ clinical syndrome.
- Patients who carry the HLA‑B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.
- Discontinue dolutegravir/abacavir/lamivudine as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue dolutegravir/abacavir/lamivudine if hypersensitivity cannot be ruled out, even when other diagnoses are possible.
- Following a hypersensitivity reaction to abacavir, NEVER restart dolutegravir/abacavir/lamivudine or any other abacavir‑containing product.
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.
- Severe acute exacerbations of hepatitis B have been reported in patients who are co‑infected with Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) ‑1 and have discontinued lamivudine, a component of dolutegravir/abacavir/lamivudine. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment.